Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Erdem Göker"'
Publikováno v:
Journal of Clinical Oncology. 39:e15057-e15057
e15057 Background: In women, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide. Tamoxifen is the most commonly used drug for the endocrine treatment of breast cancer. It reduces the risk of recurrence
Autor:
Burcu Çakar, Erdem Göker
Publikováno v:
Breast Disease ISBN: 9783030167912
Breast Disease ISBN: 9783319260105
Breast Disease ISBN: 9783319260105
Breast cancer is the most common cancer in women worldwide. Although various subgroups are defined according to the expression of hormones and ErbB family receptors, it is well known that this disease is more heterogeneous than its classification sys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e979c21743fa6b5c10c1a322a27ebfe
https://doi.org/10.1007/978-3-030-16792-9_35
https://doi.org/10.1007/978-3-030-16792-9_35
Autor:
Shaun Bender, M. Cobo, Dolores Isla, Agnieszka Cseh, Yongfeng Yu, K.H. Lee, Kostas N. Syrigos, Vassilis Georgoulias, Enriqueta Felip, Wei Li, Glenwood D. Goss, Alessandro Morabito, Andrea Ardizzoni, Shaoyong Lu, Erdem Göker, Hong Jian, Young Joo Min
Publikováno v:
Journal of Thoracic Oncology. 14:S1185
Autor:
Claudia Bühnemann, Andrea Fülöp, Konstantinos N. Syrigos, Wei Li, Jean-Charles Soria, Enriqueta Felip, Salih Zeki Guclu, Shirish M. Gadgeel, Dolores Isla, Shun Lu, Glenwood D. Goss, Young Joo Min, Flavio Solca, Vassilis Georgoulias, Ki Hyeong Lee, Neil W. Gibson, Manuel Cobo, Alessandro Morabito, Nicole C. Krämer, Erdem Göker, Agnieszka Cseh, Andrea Ardizzoni, E. Ehrnrooth
WOS: 000444765300010
PubMed ID: 29902295
IMPORTANCE Treatment choice for lung squamous cell carcinoma could be aided by identifying predictive biomarkers. OBJECTIVE To assess whether patient outcomes in the LUX-Lung 8 trial were associated
PubMed ID: 29902295
IMPORTANCE Treatment choice for lung squamous cell carcinoma could be aided by identifying predictive biomarkers. OBJECTIVE To assess whether patient outcomes in the LUX-Lung 8 trial were associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ed167d2979fb8e03b7aca02fbf66ad6
http://hdl.handle.net/11585/678709
http://hdl.handle.net/11585/678709
Autor:
Shirish M. Gadgeel, Vassilis Georgoulias, Ki Hyeong Lee, Claudia Bühnemann, Dolores Isla, Salih Zeki Güçlü, Erdem Göker, Enriqueta Felip, Nicholas F. Dupuis, Jean-Charles Soria, E. Ehrnrooth, Shun Lu, Manuel Cobo, Glenwood D. Goss, Nicole C. Krämer, Alessandro Morabito, Konstantinos N. Syrigos, Flavio Solca, Andrea Ardizzoni
WOS: 000405152800017
PubMed ID: 28577938
Objectives: Identification of biomarkers associated with clinical benefit may be crucial in establishing optimal treatment choice for patients with squamous cell carcinoma (SCC) of the lung after fir
PubMed ID: 28577938
Objectives: Identification of biomarkers associated with clinical benefit may be crucial in establishing optimal treatment choice for patients with squamous cell carcinoma (SCC) of the lung after fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da3d59eb9a53497c187ee7cdeb3f5937
https://hdl.handle.net/10668/11269
https://hdl.handle.net/10668/11269
Autor:
Matthias P.A. Ebert, Friedrich Overkamp, Erdem Göker, Dirk Reuter, Dirk Strumberg, Jens T. Siveke, Suayip Yalcin, Wolfgang E. Berdel, Markus Dommach, M. Bulitta, R.D. Hofheinz, Michael Kneba, Andrea Kerkhoff, Tilman Steinmetz, Frank Schlegel, Beate Schultheis, S De Dosso, Wolfgang E. Schmidt, Dirk Behringer, Robert Rohrberg
WOS: 000411827200016
PubMed ID: 28961832
Background: This randomized study was designed to investigate the superiority of gemcitabine (gem) plus nimotuzumab (nimo), an anti-epidermal growth factor receptor monoclonal antibody, compared with
PubMed ID: 28961832
Background: This randomized study was designed to investigate the superiority of gemcitabine (gem) plus nimotuzumab (nimo), an anti-epidermal growth factor receptor monoclonal antibody, compared with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db783c3dbb63d2b9a38e9f52239add02
http://hdl.handle.net/11655/15082
http://hdl.handle.net/11655/15082
Autor:
Gürsel Çok, Haydar Karakus, Münevver Erdinç, Tuncay Göksel, Erdem Göker, Ozlem Goksel, Feza Bacakoglu, Ruchan Uslu
Publikováno v:
International Journal of Clinical Oncology. 20:395-404
Chemotherapy is one of the main treatments for lung cancer, and in these patients, discontinuation of treatment due to uncontrollable hypersensitivity reactions (HSRs) is an important problem. To determine the frequency of HSRs during chemotherapy an
Autor:
Wei Li, Alessandro Morabito, M. Cobo, Dolores Isla, Flavio Solca, Nicole C. Krämer, K.H. Lee, Andrea Ardizzoni, Salih Zeki Guclu, E. Ehrnrooth, Shun Lu, Enriqueta Felip, Kostas N. Syrigos, J-C. Soria, Shirish M. Gadgeel, Vassilis Georgoulias, Neil W. Gibson, Agnieszka Cseh, Erdem Göker, Y. Joo Min, Glenwood D. Goss
Publikováno v:
Journal of Thoracic Oncology. 12:S2217-S2218
Autor:
Y.J. Min, Shaun Bender, Vassilis Georgoulias, M. Cobo, Alessandro Morabito, Andrea Ardizzoni, Dolores Isla, Enriqueta Felip, Wei Li, K.H. Lee, Agnieszka Cseh, Shaoyong Lu, Erdem Göker, Kostas N. Syrigos, Glenwood D. Goss
Publikováno v:
Annals of Oncology. 29:viii521
Autor:
Shirish M. Gadgeel, Young Joo Min, Manuel Cobo, Enriqueta Felip, Erdem Göker, Salih Zeki Guclu, Alessandro Morabito, Dolores Isla, Ki Hyeong Lee, Wei Li, Shun Lu, Jean-Charles Soria, Vassileios Georgoulias, Glenwood D. Goss, Andreas Ardizzoni, Konstantinos N. Syrigos, Vikram K. Chand, Bushi Wang
Publikováno v:
11.1 Lung Cancer.
Background: A is an irreversible ErbB family blocker that has shown clinical activity in pts with SCC of the head/neck and lung. This phase III trial prospectively compared A and E in pts with SCC of the lung following failure of platinum-based first